Universität zu Köln

de Zeeuw, Dick ORCID: 0000-0003-3434-7777, Bekker, Pirow, Henkel, Elena, Hasslacher, Christopher, Gouni-Berthold, Ioanna, Mehling, Heidrun, Potarca, Antonia, Tesar, Vladimir, Heerspink, Hiddo J. Lambers and Schall, Thomas J. (2015). The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol., 3 (9). S. 687 - 697. NEW YORK: ELSEVIER SCIENCE INC. ISSN 2213-8587

Full text not available from this repository.

Abstract

Background Patients with type 2 diabetes and nephropathy have high cardiorenal morbidity and mortality despite optimum treatment including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Residual risk is related to residual albuminuria. We assessed whether CCX140-B, a selective inhibitor of C-C chemokine receptor type 2 (CCR2), could further reduce albuminuria when given in addition to standard care, including ACE inhibitors or ARBs. Methods In this randomised, double-blind, placebo-controlled clinical trial, we recruited patients from 78 research centres in Belgium, Czech Republic, Germany, Hungary, Poland, and the UK. We enrolled patients with type 2 diabetes aged 18-75 years with proteinuria (first morning void urinary albumin to creatinine ratio [U-ACR] 100-3000 mg/g), estimated glomerular filtration rate of 25 mL/min per 1.73 m(2) or higher, and taking stable antidiabetic treatment and ACE inhibitors or ARBs, for at least 8 weeks before study entry. Patients were stratified based on baseline U-ACR and renal function (estimated glomerular filtration rate), and then randomly assigned (1: 1: 1) via an interactive web response system with a minimisation algorithm to oral placebo, 5 mg CCX140-B, or 10 mg CCX140-B once a day. The 12-week dosing period in the initial protocol was extended to 52 weeks by protocol amendment. The primary efficacy measure was change from baseline in U-ACR during 52 weeks in the modified intention-to-treat population (all patients with uninterrupted dosing, excluding patients who stopped dosing at week 12 either permanently under the original protocol, or temporarily because of delay in approval of the protocol amendment). We did safety analyses on all randomly assigned patients who received at least one dose of study drug. According to a prespecified analysis plan, we analysed the primary endpoint with one-sided statistical testing with calculation of upper 95% confidence limits of the differences between active and control. Findings The study ran from Dec 7, 2011 (first patient enrolled), until Aug 4, 2014. We enrolled 332 patients: 111 were assigned to receive placebo, 110 to 5 mg CCX140-B, and 111 to 10 mg CCX140-B. Of these, 192 were included in the modified intention-to-treat population. U-ACR changes from baseline during 52 weeks were -2% for placebo (95% CI -11% to 9%), -18% for 5 mg CCX140-B (-26% to -8%), and -11% for 10 mg CCX140-B (-20% to -1%). We recorded a -16% difference between 5 mg CCX140-B and placebo (one-sided upper 95% confidence limit -5%; p=0.01) and a -10% difference between 10 mg CCX140-B and placebo (upper 95% confidence limit 2%; p=0.08). Adverse events occurred in 81 (73%) of 111 patients in the placebo group versus 71 (65%) of 110 patients in the CCX140-B 5 mg group and 68 (61%) of 111 patients in the CCX140-B 10 mg group; there were no renal events during the study. Interpretation Our data suggest that CCR2 inhibition with CCX140-B has renoprotective effects on top of current standard of care in patients with type 2 diabetes and nephropathy.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code de Zeeuw, Dick UNSPECIFIED orcid.org/0000-0003-3434-7777 UNSPECIFIED Bekker, Pirow UNSPECIFIED UNSPECIFIED UNSPECIFIED Henkel, Elena UNSPECIFIED UNSPECIFIED UNSPECIFIED Hasslacher, Christopher UNSPECIFIED UNSPECIFIED UNSPECIFIED Gouni-Berthold, Ioanna UNSPECIFIED UNSPECIFIED UNSPECIFIED Mehling, Heidrun UNSPECIFIED UNSPECIFIED UNSPECIFIED Potarca, Antonia UNSPECIFIED UNSPECIFIED UNSPECIFIED Tesar, Vladimir UNSPECIFIED UNSPECIFIED UNSPECIFIED Heerspink, Hiddo J. Lambers UNSPECIFIED UNSPECIFIED UNSPECIFIED Schall, Thomas J. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-395692
DOI:	10.1016/S2213-8587(15)00261-2
Journal or Publication Title:	Lancet Diabetes Endocrinol.
Volume:	3
Number:	9
Page Range:	S. 687 - 697
Date:	2015
Publisher:	ELSEVIER SCIENCE INC
Place of Publication:	NEW YORK
ISSN:	2213-8587
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MONOCYTE CHEMOATTRACTANT PROTEIN-1; REDUCTION; TARGET Multiple languages Endocrinology & Metabolism Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/39569